Iridex and Imperial College Healthcare NHS Trust announce collaborative MicroPulse TLT study

News
Article

The partnership establishes a large-scale enrollment platform for research on MicroPulseTransscleral Laser Therapy (TLT)

A photo of London at sunset. Image credit: ©IRStone – stock.adobe.com

The Western Eye Glaucoma Department of the Imperial College Healthcare NHS Trust is the first to implement MicroPulseTLT as part of this clinical research registry, adhering to NICE IPG692 guidelines. Image credit: ©IRStone – stock.adobe.com

Iridex Corp and Imperial College Healthcare NHS Trust in London announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulseTransscleral Laser Therapy (TLT) using Iridex’s Cyclo G6 Laser and the MicroPulse P3 delivery device.

According to a news release from Iridex, the partnership establishes a large-scale enrollment platform to advance clinical research.

"The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward multicentre participation enabling a large-scale view and significant in-country impact of our MicroPulse technology,” David I. Bruce, president and CEO of Iridex, said in the release.

The company noted the study, titled "MicroPulse Transscleral Laser Therapy: A Prospective UK Study," is set to expand Iridex’s global clinical portfolio through its commitment to funding essential components of the 3-year study, and by providing a custom-designed and secure database management system.

Professor Philip Bloom, Consultant Ophthalmic Surgeon at Imperial College Healthcare NHS Trust, emphasised the importance of rapid expansion.

“We are delighted at Imperial to be able now to offer this minimally invasive treatment for glaucoma. Expansion to include other units will be crucial in advancing glaucoma treatment in the UK,” Bloom said in the news release. “Our partnership with Iridex is key to enhancing this study's reach and impact.”

Moreover, the company noted in the news release, the Western Eye Glaucoma Department of the Imperial College Healthcare NHS Trust is the first to implement MicroPulseTLT as part of this clinical research registry, adhering to NICE IPG692 guidelines. The registry and study is structured for expanded participation from other UK providers to join the program and build enrollment for large patient cohorts.

Iridex and Imperial College Healthcare NHS Trust stated their collaborative team is focused on running the study in line with the strictest ethical and regulatory standards. Investigators look forward to welcoming additional sites to join the program. The collaboration highlights the company’s shared vision for advancing medical science with MicroPulse TLT. It promises significant insights and advancements in glaucoma laser therapy, potentially revolutionising treatment approaches and enhancing patient care.

Iridex noted clinical trial training, service, and support is being provided by Chesham, England-based Carleton Optical Equipment Ltd.

Reference

1. Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust. News release. IRIDEX Corporation. Published January 24, 2024.
Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.